Sichuan Biokin Pharmaceutical Co Ltd banner
S

Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506

Watchlist Manager
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Watchlist
Price: 272.74 CNY 0.64% Market Closed
Market Cap: ¥112.6B

Sichuan Biokin Pharmaceutical Co Ltd
Current Portion of Long-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Sichuan Biokin Pharmaceutical Co Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Current Portion of Long-Term Debt
¥865.4m
CAGR 3-Years
106%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Current Portion of Long-Term Debt
¥57.5m
CAGR 3-Years
55%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Current Portion of Long-Term Debt
¥40.4m
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Current Portion of Long-Term Debt
¥30.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
12%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Current Portion of Long-Term Debt
¥76.4m
CAGR 3-Years
-7%
CAGR 5-Years
-39%
CAGR 10-Years
N/A
Zhejiang Nhu Co Ltd
SZSE:002001
Current Portion of Long-Term Debt
¥3.2B
CAGR 3-Years
7%
CAGR 5-Years
20%
CAGR 10-Years
124%
No Stocks Found

Sichuan Biokin Pharmaceutical Co Ltd
Glance View

Market Cap
112.6B CNY
Industry
Pharmaceuticals

Sichuan Biokin Pharmaceutical Co Ltd, nestled in the thriving economic landscape of China, is a dynamic force in the pharmaceutical industry. The company has carved a niche for itself by specializing in the production and commercialization of generic and proprietary drugs. Founded on the principles of innovation and accessibility, Biokin has dedicated its resources to the development of a wide range of pharmacological solutions that address both chronic and acute health conditions. Its state-of-the-art manufacturing facilities are complemented by rigorous research and development wings, where scientists and pharmacists collaborate meticulously to forge products that meet the stringent standards of efficacy and safety. At the heart of Sichuan Biokin's business model lies a commitment to affordability and quality, a combination that has enabled it to secure a significant share of the domestic pharmaceutical market. The company capitalizes on the economies of scale, leveraging its expansive production capabilities to reduce costs and enhance profit margins. By strategically aligning with healthcare providers and distributors, Biokin ensures its products efficiently reach hospitals, clinics, and pharmacies across the nation. This extensive distribution network not only enhances accessibility for patients but also cements Biokin’s reputation as a reliable pharmaceutical partner. Meanwhile, its growing portfolio of consumer healthcare products, alongside ongoing investments in biosimilars and more complex drug formulations, positions Biokin to thrive in the ever-evolving global healthcare arena.

Intrinsic Value
30.63 CNY
Overvaluation 89%
Intrinsic Value
Price ¥272.74
S

See Also

What is Sichuan Biokin Pharmaceutical Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
865.4m CNY

Based on the financial report for Dec 31, 2025, Sichuan Biokin Pharmaceutical Co Ltd's Current Portion of Long-Term Debt amounts to 865.4m CNY.

What is Sichuan Biokin Pharmaceutical Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
106%

Over the last year, the Current Portion of Long-Term Debt growth was 239%. The average annual Current Portion of Long-Term Debt growth rates for Sichuan Biokin Pharmaceutical Co Ltd have been 106% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett